Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Merck is strong in cash and balance sheet and will have continued growth in their highest-margin product while being greatly ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

Merck MRK is expected to face some notable headwinds over the next few years that could affect its long-term growth outlook, the most significant being the upcoming loss of exclusivity (“LOE”) for its ...

Merck MRK announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab). This version, which will be marketed as ...

Merck reported third-quarter earnings and revenue that topped estimates in part due to strong demand for its cancer immunotherapy Keytruda, and narrowed its full-year profit outlook to reflect lower ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD ...

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set a new standard in another patient group after proving its prowess as a pre- ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

On Friday, Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESAIY) (OTC:ESALF) announced results from the Phase 3 LEAP-015 trial of Keytruda (pembrolizumab) plus Lenvima (lenvatinib), in combination ...